S&P Futures
4,323.75 -0.50 (-0.01%) Dow Futures
33,620.00 -18.00 (-0.05%) Nasdaq Futures
14,984.00 -0.75 (-0.01%) Russell 2000 Futures
1,770.20 -1.20 (-0.07%) Crude Oil
87.81 -1.01 (-1.14%) Gold
1,833.60 -13.60 (-0.74%)
Mirati Therapeutics, Inc. (MRTX)
After hours:
Chart Events
Performance Outlook
| Previous Close | 43.56 |
| Open | 43.70 |
| Bid | 40.35 x 1800 |
| Ask | 43.12 x 800 |
| Day's Range | 41.54 - 43.70 |
| 52 Week Range | 27.30 - 101.30 |
| Volume | |
| Avg. Volume | 1,334,691 |
| Market Cap | 2.935B |
| Beta (5Y Monthly) | 0.91 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -13.55 |
| Earnings Date | Nov 06, 2023 - Nov 10, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 54.24 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for MRTX
Related Research
- Mirati Therapeutics, Inc.Daily – Vickers Top Buyers & Sellers for 01/19/2022The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.RatingFair ValueEconomic Moat2 years agoArgus Research
PR NewswireMirati To Present Updated Clinical Data at ESMO Congress 2023
Mirati Therapeutics, Inc.® (NASDAQ: MRTX), a commercial stage research and development biotechnology company, today announced several presentations to be unveiled at the European Society of Medical Oncology Congress 2023 taking place October 20 to 24, 2023 in Madrid, Spain, including updated clinical data showcasing the feasibility and potential of the investigational combination of KRASG12C inhibitor, adagrasib with pembrolizumab in a study of treatment naïve patients with advanced non-small ce
- PR Newswire
Mirati Presents Two-Year Follow-Up Data from KRYSTAL-1 Study Demonstrating Durable Response and Long-Term Overall Survival at 2023 World Conference on Lung Cancer
Mirati Therapeutics, Inc.® (NASDAQ: MRTX), a commercial stage research and development, biotechnology company, today presented two-year follow-up data from a pooled analysis of the Phase 1/1b Cohort and Phase 2 Cohort A for the KRYSTAL-1 study evaluating adagrasib (KRAZATI®) in patients with non-small cell lung cancer (NSCLC) harboring a KRASG12C mutation.
- PR Newswire
Mirati Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
Mirati Therapeutics, Inc.® (NASDAQ: MRTX), a commercial stage biotechnology company, today announced that the company granted equity awards to 3 new employees with a grant date of September 1, 2023, as equity inducement awards outside of the company's 2022 Equity Incentive Plan (but under the terms of the company's Inducement Plan) and material to the employee's acceptance of employment with the company. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).
